Vaccine experts say Moderna’s Covid-19 data leave big questions

Vaccine experts say Moderna’s Covid-19 data leave big questions

eavy hearts soared Monday with news that Moderna’s Covid-19 vaccine candidate – the frontrunner in the American market – seemed to be generating an immune response in Phase 1 trial subjects. The company’s stock valuation also surged, hitting $29 billion, an astonishing feat for a company that currently sells zero products.

By Miki

Leave a Reply

Your email address will not be published. Required fields are marked *